10 Most Profitable Growth Stocks to Buy
On May 26, Michael Dehal, Senior Portfolio Manager at Dehal Investment Partners of Raymond James Ltd., appeared on BNN Bloomberg to discuss the outlook for the markets.
Posts Tagged ‘NASDAQ:ASND’
Ascendis Pharma A/S (NASDAQ:ASND) Q1 2026 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the First Quarter Ascendis Pharma Earnings Conference Call.
Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential
Joseph Edelman, the billionaire chief of New York-based Perceptive Advisors, specializes in the biotechnology and life sciences sectors.
7 Best Strong Buy European Stocks to Invest In
European stocks are getting a closer look as investors search beyond the crowded parts of the U.S.
7 Fastest Growing European Stocks to Invest In
European stocks are getting a closer look again, and not only because investors want to diversify away from a crowded U.S. trade.
Ascendis Pharma (ASND) Revenue Nearly Doubles to €720M in 2025 Fueled by Core Product Growth
Ascendis Pharma (NASDAQ:ASND) is one of the best NASDAQ growth stocks to buy for the next 2 years.
10 Best NASDAQ Growth Stocks to Buy for the Next 2 Years
On February 19, Tom Lee of Fundstrat and BitMine joined 'Closing Bell' on CNBC to talk about the state of the markets.
Ascendis Pharma A/S (NASDAQ:ASND) Q4 2025 Earnings Call Transcript
Ascendis Pharma A/S (NASDAQ:ASND) Q4 2025 Earnings Call Transcript February 11, 2026Ascendis Pharma A/S misses on earnings expectations.
RBC Maintains Outperform Rating on Ascendis Pharma (ASND) Amid Growth Targets
Ascendis Pharma A/S (NASDAQ:ASND) ranks among the best high growth European stocks to buy.
BofA Reiterates Buy Rating on Ascendis Pharma (ASND) While Wells Fargo Analyst Raises PT
In other news, on January 20, TheFly reported that Wells Fargo analyst Derek Archila upgraded the price target on Ascendis Pharma from $322 to $330, keeping an Overweight rating...
11 Best Stocks to Buy for Investment
Following growing uncertainty in global markets amid heightened geopolitical tensions, the U.S. market rebounded this week.
10 High Growth European Stocks To Buy
European equities began the last week of January in a sour mood, with investors concerned on January 26 about rising geopolitical tensions in anticipation of a Federal Reserve...
Ascendis Pharma A/S (ASND): A Bull Case Theory
We came across a bullish thesis on Ascendis Pharma A/S on Tip Ranks’ YouTube Channel. In this article, we will summarize the bulls’ thesis on ASND.
Ascendis Pharma A/S (NASDAQ:ASND) Q3 2025 Earnings Call Transcript
Ascendis Pharma A/S (NASDAQ:ASND) Q3 2025 Earnings Call Transcript November 12, 2025Ascendis Pharma A/S misses on earnings expectations.
UBS Maintains Buy on Ascendis (ASND), Sees Upside from Yorvipath Data
Ascendis Pharma A/S (NASDAQ:ASND) ranks among the best biotech stocks to buy.
14 Best Biotech Stocks to Buy Right Now
The biotech industry is almost always buzzing. However, there has been some unanticipated activity in this sector of late.
11 Best Performing Long Term Stocks According to Analysts
On September 19, Alli McCartney, Managing Director at UBS Private Wealth Management, and Philip Straehl, CIO Americas at Morningstar Wealth, joined CNBC to the rate cuts, market...
Morgan Stanley Remains Bullish on Ascendis Pharma (ASND)
Ascendis Pharma A/S (NASDAQ:ASND) is one of the top high growth international stocks to buy right now.
13 High Growth International Stocks to Buy Right Now
On September 12, CNBC reported that according to data released the same day, the UK economy recorded zero growth in July after expanding by 0.4% in June.
Ascendis Pharma A/S (NASDAQ:ASND) Q2 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Q2 2025 Ascendis Pharma Earnings Conference Call.
Ascendis Pharma A/S (ASND) Delivers Positive Trial Results for Hypoparathyroidism Treatment
Ascendis Pharma A/S (NASDAQ:ASND) is one of the best biotech stocks to buy according to billionaire Steve Cohen.
10 Best Biotech Stocks to Buy According to Billionaire Steve Cohen
Steve Cohen, whose success at SAC Capital made him one of the most successful hedge fund managers on Wall Street, is a worried man.
Oppenheimer Hikes Ascendis Pharma Price Target on Strong Yorvipath Demand Outlook
Ascendis Pharma A/S (NASDAQ:ASND) is one of billionaire Stan Druckenmiller’s top stock picks with huge upside potential.
Billionaire Stan Druckenmiller’s 10 Stock Picks with Huge Upside Potential
Stanley Druckenmiller, an American billionaire investor, is the founder of Duquesne Capital.
Ascendis Pharma (ASND) Rated as a Hold at Cannacord Genuity on Growth Hormone Prospects
Ascendis Pharma A/S (NASDAQ:ASND) is among the 12 best healthcare stocks to buy now.
12 Best Healthcare Stocks to Buy Now
Healthcare companies in the US are facing policy headwinds under President Donald Trump's Administration.
BofA Hikes Ascendis Pharma Price Target to $216 Affirms Buy Rating
Ascendis Pharma A/S (NASDAQ:ASND) is one of the best 52-week high stocks to buy, according to analysts.
10 Best 52-Week High Stocks to Buy According to Analysts
Volatility in the equity markets under President Donald Trump has already hit record highs. Amid the heightened volatility, US equities have also bounced back on optimism about...
TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26
Ascendis Pharma A/S (NASDAQ:ASND) is among the 13 Biotech Stocks with Huge Upside Potential.
13 Biotech Stocks with Huge Upside Potential
The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce reductions.
12 Best Growth Stocks to Buy and Hold for the Long Term
The market closed last week mostly lower, however, the S&P 500 has been up more than 7% since April 11, indicating a returning positive sentiment.
Launch of New Drug Lifted Ascendis Pharma A/S (ASND) in Q1
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Ascendis Pharma A/S (NASDAQ:ASND) Q1 2025 Earnings Call Transcript
Ascendis Pharma A/S (NASDAQ:ASND) Q1 2025 Earnings Call Transcript May 1, 2025Ascendis Pharma A/S misses on earnings expectations.
10 Best Growth Stocks to Buy According to Billionaires
The stock market has been on a rollercoaster ride for the past few weeks as the sentiment has quickly shifted from post-election bullishness to being priced in for a slow-down...
Ascendis Pharma A/S (NASDAQ:ASND) Q4 2024 Earnings Call Transcript
Ascendis Pharma A/S (NASDAQ:ASND) Q4 2024 Earnings Call Transcript February 12, 2025Ascendis Pharma A/S beats earnings expectations.
12 High Growth International Stocks to Invest in Now
On January 15, Jurrien Timmer, Director of Global Macro at Fidelity Management & Research Company shared his outlook for 2025.
Ascendis Pharma A/S (NASDAQ:ASND) Q3 2024 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Ascendis Pharma Third Quarter Earnings Call. At this time all participants are in a listen-only mode.
10 Largest Biotech Hedge Funds and Their Top Stock Picks
The ability to successfully make money through investment requires deep thinking and analysis.
Ascendis Pharma A/S (NASDAQ:ASND) Q2 2024 Earnings Call Transcript
Ascendis Pharma A/S (NASDAQ:ASND) Q2 2024 Earnings Call Transcript September 3, 2024Ascendis Pharma A/S misses on earnings expectations.
Ascendis Pharma A/S (ASND) Stock Soared on Unexpected Demand
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” first-quarter 2024 investor letter.
Ascendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call Transcript
Operator: Good day, and welcome to the Q1 2024 Ascendis Pharma Earnings Conference Call. At this time, all participants are in a listen-only mode.
5 Fastest Growing Health Tech Companies in the World
In this article, we will be taking a look at the 5 fastest growing health tech companies in the world.
Ascendis Pharma A/S (ASND) Rose on Positive Trial Results
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” fourth-quarter investor letter.
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world.
Ascendis Pharma A/S (ASND) Faced R&D Setbacks in Q4
Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here.
Ascendis Pharma A/S (NASDAQ:ASND) Q4 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Fourth Quarter 2023 Ascendis Pharma Earnings Conference Call.
Ascendis Pharma A/S (NASDAQ:ASND) Q3 2023 Earnings Call Transcript
Operator: Hello, and welcome to Ascendis Pharma Third Quarter 2023 Earnings Conference Call and Webcast.
Here’s What Caused the Volatility in Ascendis Pharma A/S (ASND)
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter investor letter.
Ascendis Pharma A/S (NASDAQ:ASND) Q2 2023 Earnings Call Transcript
Operator: Hello, and welcome to Ascendis Pharma Q2 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Here’s Why Ascendis Pharma A/S (ASND) Declined in Q2
Artisan Partners, an investment management company, released its “Artisan Global Discovery Fund” second quarter 2023 investor letter.
Hedge Fund Resource Center
